Sigyn Therapeutics, Inc. (OTCQB: SIGY) released a shareholder update authored by CEO Jim Joyce, detailing the company's strategic initiatives including a potential merger with a Nasdaq-listed company at risk of delisting and the sale of certain assets. The update comes as the company seeks to overcome financial hurdles that have hindered its ability to capitalize on its therapeutic developments.
Joyce, who previously founded Aethlon Medical and oversaw the development of the Hemopurifier, highlighted Sigyn's lead candidate, CardioDialysis, a dialysis-like therapy designed to address cardiovascular disease, sepsis, and traumatic brain injury (TBI). CardioDialysis targets cholesterol-transporting lipoproteins and inflammatory molecules, offering a potential treatment for conditions that currently have limited therapeutic options. Unlike existing lipoprotein apheresis devices restricted to fewer than 60 specialized centers in the U.S., CardioDialysis is designed for use on dialysis machines available at over 7,500 clinics nationwide.
The company's challenges stem from its failed attempt to uplist to Nasdaq. Joyce explained that a firm commitment financing led by a FINRA member broker-dealer was supported by the same investor group that previously succeeded with Aethlon Medical. However, Nasdaq's requirement to review investors before an effective SEC registration statement created a catch-22, leading to the withdrawal of the registration statement. "While share price and exchange does not impact the ability of our therapies to address life-threatening disease conditions, it has clearly impacted our ability to capitalize our endeavors without harming shareholder value," Joyce stated.
To navigate forward, Joyce referenced a January 15th shareholder update outlining strategies including the sale of certain assets and a potential merger with a Nasdaq-listed company at risk of not meeting the forthcoming $5 million minimum market value of listed securities (MVLS) requirement. The update encourages shareholders to review the earlier communication for detailed strategies. Joyce also noted the company's TBI indication has emerged as a valuable asset that could be leveraged through a strategic transaction.
Despite these challenges, Joyce expressed pride in Sigyn's advancements, emphasizing that CardioDialysis has been validated in in vitro studies to reduce sepsis-inducing bacterial toxins and inflammatory mediators. He pointed to Spectral Medical's PMX hemoadsorption device, which targets endotoxin and has achieved a market value of approximately $300 million, as a comparable opportunity. As of March 11, 2026, Sigyn has 2,330,042 shares outstanding.
For further details, Joyce directed shareholders to the full update available at Sigyn Therapeutics' investor page.
